Vestal Point Capital, LP 13F holdings, Q3 2024
Holdings as of September 30, 2024 · filings on SEC EDGAR · latest filing →
Vestal Point Capital, LP disclosed 67 US equity positions worth $1.3bn in its Q3 2024 13F filing. The largest position was INSM at 9.2% of the reported book, followed by JAZZ and CYTK.
What did Vestal Point Capital, LP own in Q3 2024? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | INSM Insmed Inc | Healthcare | 9.2% | $116.8m | 1,600,000 | – | |
| 2 | JAZZ Jazz Pharmaceuticals PLC | Healthcare | 7.9% | $100.3m | 900,000 | – | |
| 3 | CYTK Cytokinetics Inc | Healthcare | 6.2% | $79.2m | 1,500,000 | – | |
| 4 | NARIUSD Inari Medical Inc | 5.0% | $63.9m | 1,550,000 | – | ||
| 5 | ACLXGBX Arcellx Inc | 4.4% | $56.4m | 675,000 | – | ||
| 6 | GPCR Structure Therapeutics Inc | Healthcare | 4.0% | $50.5m | 1,150,000 | – | |
| 7 | 4XC1 KalVista Pharmaceuticals Inc | 3.7% | $46.3m | 4,000,000 | – | ||
| 8 | CATBUSD Astria Therapeutics Inc | 3.5% | $44.0m | 4,000,000 | – | ||
| 9 | IMTX Immatics NV | Healthcare | 3.4% | $42.8m | 3,750,000 | – | |
| 10 | RARE Ultragenyx Pharmaceutical Inc | Healthcare | 3.3% | $41.7m | 750,000 | – | |
| 11 | ASND Ascendis Pharma A/S | Healthcare | 2.9% | $37.3m | 250,000 | – | |
| 12 | SLNOEUR Soleno Therapeutics Inc | 2.9% | $36.4m | 720,000 | – | ||
| 13 | DAWNGBX Day One Biopharmaceuticals Inc | 2.7% | $34.8m | 2,500,000 | – | ||
| 14 | SVRA Savara Inc | Healthcare | 2.7% | $34.3m | 8,090,000 | – | |
| 15 | AGIO Agios Pharmaceuticals Inc | Healthcare | 2.7% | $33.8m | 760,000 | – | |
| 16 | XENE Xenon Pharmaceuticals Inc | Healthcare | 2.6% | $32.5m | 825,000 | – | |
| 17 | BMRN BioMarin Pharmaceutical Inc | Healthcare | 2.2% | $28.1m | 400,000 | – | |
| 18 | QURE uniQure NV | 1.8% | $23.4m | 4,750,000 | – | ||
| 19 | JANX Janux Therapeutics Inc | Healthcare | 1.7% | $22.0m | 485,000 | – | |
| 20 | BDTX Black Diamond Therapeutics Inc | 1.7% | $21.9m | 5,028,500 | – | ||
| 21 | SLDB Solid Biosciences Inc | Healthcare | 1.5% | $19.5m | 2,800,000 | – | |
| 22 | EW Edwards Lifesciences Corp | Healthcare | 1.4% | $18.1m | 275,000 | – | |
| 23 | GILD Gilead Sciences Inc | Healthcare | 1.3% | $16.8m | 200,000 | – | |
| 24 | LQDA Liquidia Corp | Healthcare | 1.2% | $15.0m | 1,500,000 | – | |
| 25 | A Agilent Technologies Inc | Healthcare | 1.2% | $14.8m | 100,000 | – | |
| 26 | BMY Bristol-Myers Squibb Co | Healthcare | 1.0% | $12.9m | 250,000 | – | |
| 27 | GSK GSK PLC | Healthcare | 1.0% | $12.3m | 300,000 | – | |
| 28 | BCAX Bicara Therapeutics Inc | 0.9% | $10.8m | 425,000 | – | ||
| 29 | DNTH Dianthus Therapeutics Inc | Healthcare | 0.9% | $10.8m | 395,000 | – | |
| 30 | CRNXGBP Crinetics Pharmaceuticals Inc | 0.8% | $10.5m | 205,000 | – | ||
| 31 | 2662247D iTeos Therapeutics Inc | 0.8% | $10.5m | 1,025,000 | – | ||
| 32 | APLT Applied Therapeutics Inc | 0.8% | $9.7m | 1,145,000 | – | ||
| 33 | NRIX Nurix Therapeutics Inc | Healthcare | 0.8% | $9.5m | 425,000 | – | |
| 34 | SNY Sanofi SA | 0.7% | $8.6m | 150,000 | – | ||
| 35 | BRKR Bruker Corp | Healthcare | 0.7% | $8.6m | 125,000 | – | |
| 36 | APGE Apogee Therapeutics Inc | Healthcare | 0.6% | $8.0m | 136,500 | – | |
| 37 | ZYME Zymeworks Inc | Healthcare | 0.6% | $7.7m | 615,000 | – | |
| 38 | LXEO Lexeo Therapeutics Inc | Healthcare | 0.6% | $7.7m | 850,000 | – | |
| 39 | TARS Tarsus Pharmaceuticals Inc | Healthcare | 0.6% | $7.6m | 230,000 | – | |
| 40 | ANRO Alto Neuroscience Inc | Healthcare | 0.6% | $7.4m | 650,000 | – | |
| 41 | BDX Becton Dickinson & Co | Healthcare | 0.6% | $7.2m | 30,000 | – | |
| 42 | MDGL Madrigal Pharmaceuticals Inc | Healthcare | 0.5% | $6.4m | 30,000 | – | |
| 43 | LEGN Legend Biotech Corp | Healthcare | 0.5% | $6.1m | 125,000 | – | |
| 44 | FATE Fate Therapeutics Inc | Healthcare | 0.5% | $5.9m | 1,685,000 | – | |
| 45 | LKFT Galapagos NV | Healthcare | 0.4% | $5.2m | 180,000 | – | |
| 46 | URGN UroGen Pharma Ltd | Healthcare | 0.4% | $5.1m | 400,000 | – | |
| 47 | GLUE Monte Rosa Therapeutics Inc | 0.4% | $4.9m | 930,000 | – | ||
| 48 | GERN Geron Corp | Healthcare | 0.4% | $4.8m | 1,050,000 | – | |
| 49 | PASG Passage Bio Inc | 0.3% | $4.3m | 6,100,000 | – | ||
| 50 | ALLO Allogene Therapeutics Inc | Healthcare | 0.3% | $4.2m | 1,500,000 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.